Figure 4From: Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab High pretreatment frequency of mMDSC is associated with reduced OS. mMDSC frequencies were determined before (week 0/visit 1 (w0v1)), during (w8v5, w16v9 and w24v13) and after (follow-up (fu)) prostate GVAX/ipilimumab therapy by flow cytometry. A) A representative analysis of Lin?CD14+HLA-DR?/lo mMDSC. B) Percentage of mMDSC over follow-up. C) Kaplan meier curve for pre-treatment frequencies of mMDSC. Number of patients and corresponding median survival for each group are given. Differences between pre- and on- or post-treatment were analyzed with the repeated measures ANOVA with a post-hoc Dunnett's multiple comparisons test. Differences were considered significant when p?<?0.05, as indicated with asterisks (* p?<?0.05, ** p?<?0.01). Statistical significance of the survival distribution was analyzed by log-rank testing and indicated with the given p-value.Back to article page